Emanuele C.
- Country
- Italy
- Department
- Hematology
Research Overview
- An open-label, randomized phase III trial comparing local radiotherapy alone or combined with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial from the Fondazione Italiana Linfomi
- Phase 3 Multicenter Randomized Study of Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated Symptomatic Splenic Marginal Zone Lymphoma
- Phase 1b/3 Study of Tazemetostat with Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma Patients
Data & Insights
Has run more than one trial at 44 of 142 partner sites.
Specializations
Lymphoma Specialization
This investigator specializes in treating various forms of lymphoma, with particular emphasis on follicular lymphoma in its different stages and manifestations. The research focus includes both early-stage and advanced disease management.
- Early-stage follicular lymphoma treatment
- Advanced-stage lymphoma management
- Splenic marginal zone lymphoma
Their expertise extends to innovative treatment approaches for high tumor burden cases.
Treatment Strategies
The investigator explores diverse therapeutic approaches combining immunotherapy with conventional treatments. Their work involves evaluating various treatment combinations and durations.
- Combined immunochemotherapy protocols
- Radiotherapy combinations
- Novel therapeutic agents
A key focus is optimizing treatment duration while maintaining efficacy.
Clinical Innovation
The investigator studies novel therapeutic combinations including targeted therapies such as zanubrutinib and tazemetostat, along with established treatments like rituximab.
- Innovative drug combinations
- Treatment optimization strategies
- Progression-free survival assessment
Research focuses on developing more effective treatment protocols for lymphoma patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.